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Copyright © 2008 JCBN Summary The effects of inulin on the microbial composition and faecal characteristics in 36
healthy, formula-fed infants (average age 7.7 months) given 3 different daily dosages of native
inulin (0.75 g/day, 1.00 g/day, and 1.25 g/day) were studied. At all levels of inulin consumption,
a significant (p<0.05) reduction of potential pathogenic microorganisms such as clostridia was
found. An intake of 1.25 g/day of inulin caused a significant (p<0.05) increase of Bifido-
bacterium spp. as well as a significant (p<0.05) decline in Gram-positive cocci and coliform
bacteria. Inulin consumption resulted in a significant (p<0.05) decrease in faecal pH value and
changes in faecal weight, faecal texture and colour, indicating improvement in healthy bile
production and bacterial fermentation. It is concluded that inulin consumption in formula-fed
infants after weaning positively affected the microbial composition of faeces and faecal
properties.
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Introduction
The β-(2-1)-fructans inulin and oligofructose or fructo-
oligosaccharides (FOS), are natural carbohydrates, found in
many foods such as leek, garlic, onion, artichoke, chicory,
banana, asparagus and wheat [1, 2]. Based on consumption
data, the average intake of inulin and FOS in a normal
human diet has been estimated at about 2–10 g per day [1, 3].
These carbohydrates resist hydrolysis and digestion in
stomach and small intestine, and thus reach the colon intact.
There they are fermented by the colonic microbiota to short
chain fatty acids (SCFA) and gas. Selective fermentation of
these fructans by bifidobacteria can result in an improved
composition of gut microflora. This so-called prebiotic
effect has been found in many human studies with adult
volunteers [4] and with different types of inulin [5–9]. In
vitro studies also showed that oligofructose and inulin
selectively stimulated the growth of bifidobacteria [10].
FOS and inulin not only exert local colonic physiological
effects, but also systemic effects, via the absorption of their
fermentation products (SCFA) from the colon. The local
effects of inulin consumption comprise the increased
synthesis of vitamins, an increase in mineral, especially of
calcium absorption from the colon [11], and possibly a
lowered risk for colon cancer [12]. The systemic effects
include a lowered level of serum lipids [13], an increased
feeling of satiety and decreased energy intake [14, 15], or the
modulation of immune functions [16].
Most of these prebiotic studies have been carried out with
adult volunteers, but the potential physiological benefits are
equally important for infants. Not surprisingly thereforeW.K.W. Yap et al.
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prebiotics studies are also being conducted in younger
people. Changes in composition of the colonic microbiota
[17] and the possible health benefits of a mixture of galacto-
oligosaccharides and inulin in formula-fed babies were
reported [18]. Native inulin reportedly has a prebiotic effect
in formula-fed babies [19]. However, very little work if at all
has been reported on the effects of native inulin in infants of
older ages (past weaning) and the lowest dose that will give
a demonstrable physiological effect in infants. The objective
of this study is to investigate the effect of 3 different levels
(0.75 g/day; 1.00 g/day and 1.25 g/day) of native inulin
supplements on the composition of the colonic microbiota




Healthy, free-living, 5–12 months old infants from
Serdang, who had undergone no antibiotic treatments during
the previous three months, participated in the study. The
parents of the infants (23 girls and 13 boys, with an average
age of 8.1 ± 1.6 months; average weight 7.9 ± 1.4 kg and
average height of 68.0 ± 3.8 cm at the time of study) were
fully informed both orally and in written form about the aims
of the study and the procedures. The children were all past
weaning age. The protocol was approved by the Ethics
Committee of Faculty of Medicine, Universiti Putra Malaysia
(Ref. no: UPM/FPSK/100-11/40, dated 10 October 2001)
and informed consent of the parents was obtained.
Experimental design
All the participating subjects were fully supplied with
control diet (consisting of a follow-up infant formula,
different types of Nestum® baby food, biscuits), disposable
nappies and other facilities such as medical services
throughout the study. The 36 subjects were randomly
assigned to receive three levels of inulin supplementation,
added into their bottle of infant formula during preparation,
at the specified dose. Native inulin (Frutafit® IQ) with
average degree of polymerization of 9 was supplied by
Sensus, Netherlands.
The children were subjected to seven days of basal diet,
followed by either 0 g/day (n = 8), 0.75 g/day (n =1 0 ,
Group I), 1.0 g/day (n = 9, Group II) and 1.25 g/day (n =9 ,
Group III) of inulin for fourteen days and another fourteen
days of washout period. The total number of days for each
trial is 35 days.
Assessment of dietary intake and stool condition
Throughout the study, the parents of the subjects were
required to complete a daily dietary recall questionnaire,
which provided information about dietary pattern, possible
intestinal discomfort (flatulence, soft stools or diarrhoea) as
well as frequency of defecation and appearance of stools.
The consistency of the stools were classified into 5 categories
i.e. watery, soft, muddy, hard cylindrical and very hard
pellets and their colours were classified into 3 categories
greenish or yellowish, golden (light or dark), and brown
(brownish or dark).
Sample collection
The last three days of each treatment fresh stools were
collected (72 h collection) i.e. during the basal period,
during the supplementation period and during the washout
period. The stool sample was taken after mixing all stools
from the 72 h collection.
Bacteriological analyses (modified [7])
All fresh faeces samples were transported back to the
laboratory anaerobically at below 10°C within 60 min.
Samples were weighed and pH was measured in a 10%
(w/w) suspension in demineralised water. A sample was
homogenized in 0.1 mol/l (pH 7.0) potassium phosphate
buffer to obtain 0.1 g/ml faecal suspension. Serial dilutions
(10−2 to 10−11) were prepared using half strength peptone
water (Merck, Darmstadt, Germany). An aliquot of 0.1 ml of
each dilution was spread plated (in duplicate) onto agar
medium specific for the growth of total anaerobes (Wilkins-
Chalgren anaerobic agar, Oxoid-Unipath Ltd., Basingstoke,
Hampshire, England), bifidobacteria (Modified Trypticase-
Phytone-Yeast Extract agar, Scharlau, Spain), lactobacilli
(Rogosa SL agar, Merck), coliforms (MacConkey #2,
Oxoid-Unipath Ltd.), clostridia (Reinforced Clostridia agar,
Pronadisa, Madrid, Spain), Gram-positive cocci (Azide
Blood agar, Pronadisa) and total aerobes (Nutrient agar,
Merck). For recovery of anaerobic bacteria (bifidobacteria,
clostridia, coliforms, lactobacilli, total anaerobes and
Gram-positive cocci) the plates were incubated at 37°C for
three days. Anaerobic conditions were achieved by using
anaerobic jars containing Anaerocult A (Merck). For
recovery of total aerobes, the plates were incubated at 37°C
for 24 h. All plates having 30 to 300 colonies were counted
on a Quebec colony counter (Acolyte, Yorkshire, England).
Preparation of stock cultures of bifidobacteria
Ten percent of each type of colony of the bifidobacteria
plates (Modified Trypticase-Phytone-Yeast Extract agar,
TPY) was picked up and Gram-stained for morphological
observation. The colonies were purified by repeatedly
streaking on modified TPY agar. Samples of single colonies
thus obtained were subcultured twice in TPY broth at 37°C
for 18 h under anaerobic conditions. The cultures were then
subjected to centrifugation at 3000 rpm for 10 min. The
supernatant was discarded. The precipitate was mixed with
1 ml of 90% v/v glycerol in 10% w/v TPY broth and storedFaecal Characteristics of Inulin Supplemented Infants
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at −20°C until further use.
Identification of bifidobacteria
For recovery of stock cultures, the microorganisms were
grown in TPY broth anaerobically at 37°C for 48 h or more
until sufficient growth was observed. The cultures were
again subcultured twice before analysis. Gram-staining and
morphological observation was performed according to a
standard method [20]. The carbohydrate fermentation
profile was analyzed using a commercial API 20A Kit
(Biomerieux, Marcy-l’Etoile, France) for identification of
Bifidobacterium spp. The reactions were observed after
24–48 h of incubation at 37°C. Identification was obtained
by referring to the identification table in the API 20A
Analytical Profile Index Manual (APILAB).
Statistical analysis
Data were expressed as mean ± standard deviation and
one-way Analysis of Variance (ANOVA) was performed
using MINITAB version 14 (MINITAB Inc., State College,




Table 1 summarizes the microbial composition of the
faecal samples during the various treatment periods. All
three groups of subjects had similar numbers of total
anaerobes (about 1010 cfu/g faeces) during the basal period.
This number was not affected by the intake of 0.75 or 1.0 g/
d of inulin, but decreased significantly (p<0.05) with 1.25 g/
d of inulin consumption. The total number of anaerobes
came back to the original value during the washout period of
the three groups of inulin-supplemented infants. The total
aerobe plate counts in the present study did not show any
Table 1. Faecal microbial composition during various treatment periods
Group I: 0.75 g/d of inulin during supplementation, Group II: 1.00 g/d of inulin; Group III: 1.25 g/d of inulin. Group IV:
0 g/d of inulin. Each group serve as their own control. Significant differences between groups for lactobacillus and
bifidobacteria at basal period, were unexpected, since the babies were distributed randomly without any prior knowledge
of their faecal microbiota profile. All babies were from the same area of residence.
*Significant changes as compared to basal period (p<0.05) during inulin supplementation
Bacteria Group
Bacteria in Log10 cfu/g (±SD) during
Basal period Inulin period Washout period
Total anaerobes I (n = 10) 10.57 ± 0.35 10.73 ± 0.29 10.15 ± 0.44
II (n = 9) 10.34 ± 0.18 9.89 ± 0.83 10.50 ± 0.25
III (n = 9) 10.28 ± 0.35 9.67 ± 0.30* 10.10 ± 0.12
IV (n = 8) 10.45 ± 0.35 10.46 ± 0.30 10.43 ± 0.35
Bifidobacteria I (n = 10) 9.16 ± 0.57 9.36 ± 0.58 8.91 ± 0.51
II (n = 9) 9.64 ± 0.28 9.77 ± 0.38 9.83 ± 0.26
III (n = 9) 9.23 ± 0.38 9.55 ± 0.17* 9.56 ± 0.34
IV (n = 8) 9.05 ± 0.41 9.04 ± 0.32 9.32 ± 0.39
Lactobacilli I (n = 10) 8.61 ± 0.93 8.90 ± 0.68 8.70 ± 0.56
II (n = 9) 9.61 ± 0.15 8.86 ± 0.15* 9.31 ± 0.19
III (n = 9) 8.78 ± 0.43 8.15 ± 0.75 8.20 ± 0.71
IV (n = 8) 5.92 ± 0.51 5.01 ± 0.52 6.13 ± 0.43
Coliforms I (n = 10) 8.51 ± 0.38 8.44 ± 0.58 9.23 ± 0.61
II (n = 9) 8.85 ± 0.69 8.50 ± 0.46 8.79 ± 0.47
III (n = 9) 9.68 ± 0.32 8.13 ± 0.40* 8.80 ± 0.49
IV (n = 8) 9.22 ± 0.35 9.26 ± 0.52 9.41 ± 0.56
Clostridia I (n = 10) 10.15 ± 0.15 9.28 ± 0.35* 9.34 + 0.55
II (n = 9) 9.98 ± 0.32 8.95 ± 0.20* 10.20 + 0.35
III (n = 9) 9.66 ± 0.32 8.78 ± 0.39* 9.59 + 0.25
IV (n = 8) 9.87 ± 0.24 9.88 ± 0.23 9.89 ± 0.25
Gram-positive cocci I (n = 10) 9.76 ± 0.71 8.74 ± 0.55* 8.78 ± 0.55
II (n = 9) 9.38 ± 0.62 8.88 ± 0.27 10.04 ± 0.42
III (n = 9) 9.12 ± 0.42 8.42 ± 0.28* 9.10 ± 0.67
IV (n = 8) 9.05 ± 0.53 9.21 ± 0.44 9.66 ± 0.59W.K.W. Yap et al.
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significant changes (p>0.05) during any of the treatments
(not shown).
All levels of inulin supplementation had a significant
effect (p<0.05) on the numbers of clostridia. The initial
numbers of clostridia in the studied groups were high
(1010 cfu/g faeces) during basal diet and were reduced with
almost 1 log unit during different levels of inulin supple-
mentation.
The distribution of Gram-positive cocci in the beginning
of basal period remained at 109 cfu/g faeces, but showed a
significant reduction (p<0.05) during both 0.75 g/d and
1.25 g/d inulin consumption whereas no significant differ-
ence (p>0.05) was seen with 1.0 g/d inulin intake. The total
number of coliforms amounted to 108–109 cfu/g faeces. Only
a slight decrease of coliforms was found with 0.75 g/d and
1.00 g/d of inulin supplementation whereas a significant
decrease (p<0.05) in coliforms was shown in the 1.25 g/d
inulin supplementation.
The numbers of bifidobacteria during inulin supplementa-
tion showed a non-significant increase with both 0.75 g/d
and 1.00 g/d of inulin intake, whereas with 1.25 g/d of inulin
a significant increase (p<0.05) in bifidobacteria numbers
was found. At this inulin consumption the magnitude of the
bifidogenic effect seemed dependent on the starting number
of bifidobacteria (Fig. 1).
In the present study no stimulation of Lactobacillus
growth was found. The numbers of lactobacilli isolated from
the fresh faeces were in the range of 108–109 cfu/g in most of
the infants. Only 1 g/d inulin showed a significant decrease
in lactobacilli bacterial count. In the control group of 8
Fig. 1. Increase in Bifidobacterium sp. as a function of the initial number of Bifidobacterium sp. at various levels of inulin supplemen-
tation. The faecal content of Bifidobacterium sp. was determined with and without inulin supplementation of the diet, and the
logarithmic increase was calculated. The line is the best fit as calculated (by Excel).Faecal Characteristics of Inulin Supplemented Infants
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infants that did not receive inulin treatment no changes in
the microbial profile were detected during the 35 days.
Identification of Bifidobacterium isolates
The morphology of the colonies on TPY varied from
convex to lens-shaped, or convex to pulvinate. Their colour
and appearance varied from opaque to shining and from
porcelain white through whitish to cream, with an un-
dulating or smooth to mucoid-soft surface. The morphology
of the bacteria was found to be bifurcated Y and V rod-
shaped as observed under phase contrast microscopy. All
isolates were Gram-positive (blue violet to Gram-stain).
Among 78 isolates isolated from faeces collected during the
basal period without inulin, thirty six isolates were identified
as follows based on their carbohydrate fermentation pattern:
18% Bifidobacterium bifidum strain 1 (Bb 1), 64% Bifido-
bacterium bifidum strain 2 ( Bb 2) and 18% unidentified
genus under the Actinomyces grouping. The unidentified
isolates and Bifidobacterium bifidum strain 1 (Bb 1) were
differentiated by their ability to ferment arabinose.
The isolates from the periods with inulin-supplemented
diet were identified as follows: 7.7% Bb1 and 92.3% Bb2.
Apparently, inulin consumption leads to a shift in species.
Isolates that were able to ferment arabinose were identified
as  Bifidobacterium bifidum strain 1 with 97.5% of
identification. Bb1 or Bb2 are the two different strains of
B. bifidum identified through various biochemical tests.
Stool characteristics
The changes in stool characteristics in terms of pH,
consistency, frequency and weight are presented in Table 2.
Inulin ingestion led to a significant (p<0.05) reduction of the
faecal pH in the two highest dosages, in a dose dependent
manner. Changes in faecal frequency and mass were also
observed during inulin supplementation, but these effects
did not reach statistical significance.
The consistency of the stools changed from being soft,
muddy and hard cylindrical during the basal period, to
mostly soft during the three levels of inulin supplementation
as indicated by the lower numbers in Table 2. However none
of these changes reached statistical significance. Changes in
stool colour were found with inulin supplementation,
whereby the percentage number of yellow/green and lighter
coloured stools decreased and the percentage of brown or
darker coloured stools increased compared to basal treat-
ment (Fig. 2). Infants treated with 0.75 g/day inulin showed
an increase in brown stools and a reduction in yellow/
greenish stool during treatment period. During the washout
period, the number of brown stools decreased, while that of
the yellow/greenish stool increased again. Infants treated
with 1.00 g/day inulin also showed increase in the number of
brown stools and a reduction in yellow/greenish stool during
treatment. Again, during the washout period, the number of
brown stools decreased, while that of the yellow/greenish
stool increased. Infants treated with 1.25 g/day inulin
showed no significant change in stools colour during treat-
ment, followed by a significant increase in brown stools and
Table 2. Faecal characteristics
Group I: 0.75 g/d of inulin during supplementation, Group II: 1.00 g/d of inulin; Group III: 1.25 g/d of inulin. Group IV:
0 g/d of inulin. All data are given as the average ± SD. *Significant changes as compared to basal period (p<0.05) during
inulin supplementation.
Parameter Group Basal period Inulin period Washout period
Faecal pH I (n = 10) 6.8 ± 0.5 6.7 ± 0.6 6.9 ± 0.7
II (n = 9) 6.8 ± 0.6 6.3 ± 0.5* 6.6 ± 0.4
III (n = 9) 6.7 ± 0.7 5.9 ± 0.3* 6.4 ± 0.6
IV (n = 8) 7.1 ± 0.6 7.2 ± 0.4 7.4 ± 0.5
Defecation frequency 
(per day)
I (n = 10) 1.07 ± 0.25 1.13 ± 0.25 1.33 ± 0.15
II (n = 9) 1.28 ± 0.13 1.22 ± 0.18 1.17 ± 0.17
III (n = 9) 1.56 ± 0.17 1.48 ± 0.15 1.52 ± 0.15
IV (n = 8) 1.11 ± 0.19 1.12 ± 0.20 1.19 ± 0.23
Faecal mass (g/day) I (n = 10) 43.9 ± 12.8 55.8 ± 14.8 57.2 ± 12.8
II (n = 9) 44.2 ± 11.6 49.7 ± 13.8 48.5 ± 10.6
III (n = 9) 54.3 ± 14.1 58.0 ± 11.4 51.3 ± 14.1
IV (n = 8) 44.1 ± 12.9 44.2 ± 12.7 44.4 ± 12.6
Faecal consistency I (n = 10) 2.9 ± 3.7 2.4 ± 3.9 2.8 ± 4.2
[scored from 1:
 watery–5: hard pellets ]
II (n = 9) 2.3 ± 2.6 2.0 ± 2.7 1.9 ± 3.2
III (n = 9) 2.6 ± 4.2 2.1 ± 3.7 2.2 ± 4.2
IV (n = 8) 2.7 ± 3.8 2.8 ± 3.6 2.6 ± 3.9W.K.W. Yap et al.
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a significant reduction in golden stool during the washout
period. Infants not given any inulin showed no significant
change in stools colour profile.
The 8 infants in the control group showed no changes in
faecal characteristics. Other than the conditions described
above, inulin showed no other observable effects on the
general conditions (such as temperature, appetite or weight
gain) of the subjected infants.
Discussion
It is known that there are significant differences in the
colonic microbiota of breast-fed and formula-fed infants.
The colon of breast-fed infants tend to be dominated by
bifidobacteria, whereas those of formula-fed infants tend to
have more diverse and adult like microflora [21, 22]. The
present study also demonstrated a similar trend of microflora
distribution. The faecal microbiota was dominated by
bacteria such as coliforms, Gram-positive cocci and
clostridia (Table 1). Low numbers of Lactobacillus spp. and
Bifidobacterium spp. were observed in the faecal flora of
these infants, and the highest inulin supplementation studied
(1.25 g/d) led to a significant increase in bifidobacteria.
The present study also showed that with the lower levels of
inulin supplementation the number of putrefactive bacteria
could be reduced by almost one log unit. At dosages of 0.75
and 1.00 g/d no significant increase in Bifidobacterium spp.
was found.
The weak stimulation of bifidobacteria growth observed
in this study may be explained by the fact that the stimula-
tion effect of inulin or FOS is strain-specific [23,  24].
Bifidobacterium isolates collected from healthy infants in
Serdang, Malaysia mainly belong to the species B.
pseudocatenulatum [25]. Among the bifidobacteria strains
investigated, B. pseudocatenulatum demonstrated only weak
growth on inulin in vitro [ 24,  26].  In vitro studies have
demonstrated that B. longum is unable to ferment long chain
polymers such as inulin efficiently, whereas B. adolescentis
is able to metabolize inulin slightly better [24].
Fig. 2. Faecal colour during basal, treatment and washout periods
in the various infants given different levels of inulin
supplementation.
A: Infants treated with 0.75 g/day inulin showed an
increase in brown stools and a reduction in yellow/greenish
stool during treatment period. During the washout period,
the number of brown stools decreased, while that of the
yellow/greenish stool increased again. Infants not given
any inulin showed no significant change in stools colour
profile.
B: Infants treated with 1.00 g/day inulin also showed
increase in the number of brown stools and a reduction in
yellow/greenish stool during treatment. Again, during the
washout period, the number of brown stools decreased,
while that of the yellow/greenish stool increased.
C: Infants treated with 1.25 g/day inulin showed insignifi-
cant changes in stools colour during treatment, followed by
a significant increase in brown stools and a significant
reduction in golden stool during the washout period.
Dagger: Significantly different (p<0.05) from basal
Open circle: Significantly different (p<0.05) from treatmentFaecal Characteristics of Inulin Supplemented Infants
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Another factor explaining the moderate changes found in
this study may be the low daily dosage of inulins. For
prebiotic effects from native inulin to be observed in adults
at least 0.07 g/kg/day is required [9]. The lowest prebiotic
dosage reported in formula-fed infants (aged on average 12
weeks) is 1.5 g/d or 0.25 g/kg/day [19]. The dosage applied
in our study (0.1–0.16 g/kg/d) was at the lowest part of this
range. With oligofructose from inulin at 2 g/d, only a trend
for increased bifidobacteria in children aged 6–24 months
were found [27]. In paediatric patients it was found that a
mixture of FOS and inulin at 0.8 g/d led to a trend for
bifidogenic effect [28]. Our data do not deviate significantly
from these publications. Finally it may well be that the
duration of the trial is relevant, two weeks of treatment being
too short to pick up the changes.
The original number of bifidobacteria present before
inulin supplementation may also play a role. Human studies
showed no clear dose-response effect on the increase of log
number of bifidobacteria [29, 30], and it is hypothesized that
the major factor in determining the increase in the amount of
bifidobacteria is the initial number of bifidobacteria in the
faeces at the start of the inulin feeding regimen. With the
numbers already fairly high, an increase (combined with a
low daily dosage) may be difficult to detect, and then only
with the highest dosage applied here.
The decrease in faecal pH observed in this study indicated
the production of SCFA and lactate through fermentation of
inulin [31]. Stool begins green and changes to bright yellow
as it passes through the digestive system. Bile and bacteria
finally turn it brown. Yellow or green stools may indicate
that the stool is passing through the digestive tract too
quickly. Bright yellow stools may indicate insufficient bile
[32]. The increase in number of brown stools of 0.75 and
1.00 g/d inulin supplementation period indicated an
improvement in the healthy bile production and bacterial
fermentation. The reasons why infants treated with 1.25 g/
day inulin showed insignificant changes in stool colour
during treatment, but a significant increase in healthy brown
stools and a significant reduction in golden stool during the
washout period, is difficult to explained. The beneficial
effects appeared to have been delayed by the high inulin
dose, and only occurred during the washout period.
This study also showed changes in stool frequency and
consistency during inulin supplementation in formula-fed
children. However, none of these reached statistical signifi-
cance. Similar data have been published for the consumption
of FOS in children aged 32 weeks [33].
All data taken together in this study shows that the
consumption of native inulin in children aged about 8
months at 1.25 g/d leads to a prebiotic effect similar to that
observed in adults: a significant increase in the number of
faecal bifidobacteria accompanied by a decrease in poten-
tially harmful species such as clostridia.
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